Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Assets (2016 - 2025)

Perspective Therapeutics' Non-Current Assets history spans 15 years, with the latest figure at $116.3 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 3.85% year-over-year to $116.3 million; the TTM value through Sep 2025 reached $454.6 million, up 18.46%, while the annual FY2024 figure was $109.9 million, 35.64% up from the prior year.
  • Non-Current Assets for Q3 2025 was $116.3 million at Perspective Therapeutics, up from $114.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $121.0 million in Q3 2024 and bottomed at $3.1 million in Q2 2021.
  • The 5-year median for Non-Current Assets is $87.4 million (2023), against an average of $59.7 million.
  • The largest annual shift saw Non-Current Assets surged 2504.44% in 2023 before it fell 3.85% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $3.6 million in 2021, then soared by 33.66% to $4.9 million in 2022, then surged by 1562.31% to $81.1 million in 2023, then surged by 35.64% to $109.9 million in 2024, then increased by 5.81% to $116.3 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Non-Current Assets are $116.3 million (Q3 2025), $114.8 million (Q2 2025), and $113.6 million (Q1 2025).